| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| UNITED STATES | Region | 2026 | USD | 71,397.0 | 79.6% |
| Total Other Countries, Excluding United States and Ireland | Region | 2026 | USD | 18,118.0 | 20.2% |
| IRELAND | Region | 2026 | USD | 143.0 | 0.2% |
| UNITED STATES | Region | 2025 | USD | 17,171.0 | 51.2% |
| Total Other Countries, Excluding United States and Ireland | Region | 2025 | USD | 16,250.0 | 48.5% |
| IRELAND | Region | 2025 | USD | 116.0 | 0.4% |
| UNITED STATES | Region | 2024 | USD | 16,562.0 | 51.2% |
| Total Other Countries, Excluding United States and Ireland | Region | 2024 | USD | 15,689.0 | 48.5% |
| IRELAND | Region | 2024 | USD | 113.0 | 0.4% |
| UNITED STATES | Region | 2023 | USD | 16,373.0 | 52.4% |
| Total Other Countries, Excluding United States and Ireland | Region | 2023 | USD | 14,756.0 | 47.3% |
| IRELAND | Region | 2023 | USD | 98.0 | 0.3% |
| UNITED STATES | Region | 2022 | USD | 16,134.0 | 50.9% |
| Total Other Countries, Excluding United States and Ireland | Region | 2022 | USD | 15,450.0 | 48.8% |
| IRELAND | Region | 2022 | USD | 101.0 | 0.3% |
| UNITED STATES | Region | 2021 | USD | 15,525.0 | 51.6% |
| Total Other Countries, Excluding United States and Ireland | Region | 2021 | USD | 14,491.0 | 48.1% |
| IRELAND | Region | 2021 | USD | 100.0 | 0.3% |
| Cardiac and Vascular Group | Product | 2026 | USD | 13,976.0 | 38.6% |
| Neuroscience Group | Product | 2026 | USD | 10,287.0 | 28.4% |
| Medical Surgical | Product | 2026 | USD | 8,815.0 | 24.4% |
| Diabetes Group | Product | 2026 | USD | 3,112.0 | 8.6% |
| Cardiac and Vascular Group | Product | 2025 | USD | 12,481.0 | 37.3% |
| Neuroscience Group | Product | 2025 | USD | 9,846.0 | 29.4% |
| Medical Surgical | Product | 2025 | USD | 8,407.0 | 25.1% |
| Diabetes Group | Product | 2025 | USD | 2,755.0 | 8.2% |
| Cardiac and Vascular Group | Product | 2024 | USD | 11,831.0 | 36.8% |
| Neuroscience Group | Product | 2024 | USD | 9,406.0 | 29.3% |
| Medical Surgical | Product | 2024 | USD | 8,417.0 | 26.2% |
| Diabetes Group | Product | 2024 | USD | 2,488.0 | 7.7% |
| Cardiac and Vascular Group | Product | 2023 | USD | 11,573.0 | 37.1% |
| Neuroscience Group | Product | 2023 | USD | 8,959.0 | 28.7% |
| Medical Surgical | Product | 2023 | USD | 8,433.0 | 27.0% |
| Diabetes Group | Product | 2023 | USD | 2,262.0 | 7.2% |
| Cardiac and Vascular Group | Product | 2022 | USD | 11,423.0 | 36.1% |
| Medical Surgical | Product | 2022 | USD | 9,141.0 | 28.9% |
| Neuroscience Group | Product | 2022 | USD | 8,784.0 | 27.7% |
| Diabetes Group | Product | 2022 | USD | 2,338.0 | 7.4% |
| Cardiovascular Portfolio | Product | 2021 | USD | 10,772.0 | 35.8% |
| Medical Surgical Portfolio | Product | 2021 | USD | 8,737.0 | 29.0% |
| Neuroscience Portfolio | Product | 2021 | USD | 8,195.0 | 27.2% |
| Diabetes Operating Unit | Product | 2021 | USD | 2,413.0 | 8.0% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
